Shared resources lie at the heart of scientific progress by the Case Comprehensive Cancer Center’s own members and affiliated investigators. The Center continually elevates its research capacity by investing in leading-edge resources, including modernistic tools of cancer investigation.
The shared resources are supported by the Cancer Center Support Grant (CCSG) from the National Cancer Institute. Additional support may be provided from other sources, such as chargeback systems and institutional funding. The support from the CCSG allows the core facilities to provide benefits to Cancer Center members, such as ensured access to services.
Remember to acknowledge the valuable services provided by Cancer Center Core Facilities in your research papers and publications: "This research was supported by the [insert name] Core Facility of the Case Comprehensive Cancer Center (P30 CA043703)."
Marty Veigl, PhD
When a team of researchers at the Case Comprehensive Cancer Center wanted to study the link between genetic variants and the risk of developing colon cancer, they relied on the expertise of the Gene Expression & Genotyping Facility (GEGF) and its director, Marty Veigl, PhD, Associate Professor of General Medical Sciences (Oncology).
Recent studies identified 15-Hydroxyprostaglandin dehydrogenase (15-PGDH) as a novel colon cancer suppressor, which means that loss of the gene function could result in an increased risk of colon cancer. A team of researchers led by Li Li, MD, PhD, Associate Director for Prevention Research at the Case CCC and Professor of Family Medicine at the CWRU SOM, hoped to build upon these findings to determine whether 15-PGDH is a colon cancer susceptibility gene, and if it plays a role in colon cancer carcinogenesis in the general population.